Latest medullary thyroid cancer Stories

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has notified GlaxoSmithKline (GSK) that it has achieved proof-of-concept for XL184 under the collaboration agreement between GSK and Exelixis, and has submitted the corresponding data report to GSK. Under the agreement, GSK has 90 days to review the data and decide whether to exercise its option to select the compound for further development and commercialization. If GSK selects XL184, Exelixis would receive a $55 million milestone...

San Francisco-based biotech Exelixis has seen its shares rise after taking an investigational thyroid cancer drug into a Phase III trial. While the relatively low incidence of medullary thyroid cancer will limit the drug's commercial potential, the low barriers to market entry and high unmet need should help its chances of success, ultimately leading to a satisfactory return on development costs. The Phase III registrational trial is a randomized double-blind study evaluating XL184...

Exelixis has initiated the Phase III registration trial of XL184 as a potential treatment for medullary thyroid cancer. The Phase III trial is a randomized, placebo-controlled, double-blinded study of XL184 as single-agent therapy in 315 patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Patients will be randomized in a 2:1 ratio to receive XL184 or placebo administered as a daily oral dose. The primary endpoint will be duration of progression-free...

Exelixis, Inc. (Nasdaq:EXEL) announced today that the phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) has been initiated. XL184 is a small molecule anticancer compound targeting the MET, RET, and VEGFR2 receptor tyrosine kinases. Recently, Exelixis and the U.S. Food and Drug Administration (FDA) reached agreement on the phase 3 registration trial via the Special Protocol Assessment process. Exelixis has also discussed the trial design with...

Exelixis and the FDA have reached agreement on the Phase III registration trial of XL184, a small molecule anticancer compound targeting MET, RET, and VEGFR2, via the special protocol assessment process. Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the Phase III trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) this summer. The Phase III trial will be a randomized, placebo-controlled, double-blinded...

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of XL184, a small molecule anticancer compound targeting MET, RET, and VEGFR2, via the Special Protocol Assessment process. Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the phase 3 trial of XL184 as a potential...